1. Scrip
  2. >>Business
  3. >>Strategy

Spotlight On Israel: Compugen Comes Forth

 
• By Lucie Ellis-Taitt

Compugen, a predictive drug discovery and development company, plays an important role within Israel's biopharma sector as one of the oldest businesses in an immature market. Building on its 25-year history, the company is about to embark on a new challenge: clinical development.

Compugen Quote
Compugen offices in Holon, Israel • Source: Lucie Ellis

Compugen Ltd. is an example of success for Israel's emerging biopharma industry. The company's long journey to clinical drug development spans many years and covers several evolutionary steps, from a computational service provider to early-stage research leader and critical employer for the Israeli biopharma sector.

In an exclusive interview with Scrip, Compugen's president and CEOAnat Cohen-Dayag talks about that journey, the company's pipeline of immuno-oncology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.